HC Wainwright Has Pessimistic Outlook of Valneva Q2 Earnings

Valneva SE Sponsored ADR (NASDAQ:VALN) – Research analysts at HC Wainwright dropped their Q2 2026 earnings per share estimates for shares of Valneva in a research note issued on Thursday, May 14th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings of ($0.28) per share for the quarter, down from their previous estimate of ($0.21). The consensus estimate for Valneva’s current full-year earnings is ($0.81) per share. HC Wainwright also issued estimates for Valneva’s Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.09) EPS, FY2026 earnings at ($1.00) EPS, FY2027 earnings at $1.89 EPS, FY2028 earnings at $2.22 EPS, FY2029 earnings at $2.38 EPS and FY2030 earnings at $4.13 EPS.

Valneva (NASDAQ:VALN) last released its quarterly earnings results on Tuesday, March 31st. The company reported ($0.42) EPS for the quarter. The company had revenue of $35.77 million for the quarter. Valneva had a negative return on equity of 107.63% and a negative net margin of 88.87%.

Several other equities analysts have also commented on VALN. Wall Street Zen raised Valneva from a “strong sell” rating to a “sell” rating in a research report on Saturday. Guggenheim set a $11.00 target price on Valneva in a research report on Thursday, April 16th. Finally, The Goldman Sachs Group lowered Valneva from a “neutral” rating to a “sell” rating and set a $4.90 target price on the stock. in a research report on Wednesday, April 22nd. Three equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $11.98.

Valneva Stock Performance

Valneva stock opened at $5.71 on Tuesday. The stock’s 50 day moving average price is $6.98 and its 200 day moving average price is $8.56. The firm has a market capitalization of $541.82 million, a PE ratio of -3.05 and a beta of 1.72. The company has a debt-to-equity ratio of 2.14, a quick ratio of 1.60 and a current ratio of 2.14. Valneva has a one year low of $5.06 and a one year high of $12.25.

Institutional Investors Weigh In On Valneva

Several hedge funds have recently modified their holdings of the stock. Marex Group plc purchased a new stake in shares of Valneva during the second quarter valued at $64,000. XTX Topco Ltd purchased a new stake in shares of Valneva during the fourth quarter valued at $94,000. JPMorgan Chase & Co. purchased a new stake in shares of Valneva during the third quarter valued at $124,000. VSM Wealth Advisory LLC lifted its holdings in shares of Valneva by 125.0% during the third quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock valued at $110,000 after purchasing an additional 5,000 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in shares of Valneva during the fourth quarter valued at $44,000. 11.39% of the stock is owned by hedge funds and other institutional investors.

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.